CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
mavacamtendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03496168
NCT03496168Phase 2Completed
CompareCT.gov

An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)

Bristol-Myers Squibb·interventional·Posted Apr 12, 2018·Updated Jan 9, 2025

In Brief

A Phase 2 clinical trial evaluating mavacamten for Hypertrophic Cardiomyopathy. Completed, enrolled 13 participants across 4 sites.

Detailed Summary

This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertrophic Cardiomyopathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 12, 2018
Enrollment StartApr 26, 2018
Primary CompletionNov 9, 2023
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 8.2 years ago

Interventions

mavacamtendrug

mavacamten capsules